Language: BG BG
nav.cta
← Back to results
Active (not recruiting) Phase 3 2023-504026-19-01

Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Phase 3 – large-scale trial before approval
Conditions: Prostate Cancer

Sponsor: Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH

trial.available_in: БГ
Overview
Trial status: Authorised Confidential commercial information
Who can participate
Age group: 18-64 years, 65+ years Gender: Male Target enrollment: 394 participants
Interventions
RADELUMIN 2000 MBq/ml solution injectable
Drug
RADELUMIN 1300 MBq/ml solution injectable
Drug
Radelumin 2000 MBq/ml Injektionslösung
Drug
RADELUMIN 1300 MBq/ml solution injectable
Drug
Radelumin 2000 MBq/mL solución inyectable
Drug
Radelumin 2000 MBq/ml oplossing voor injectie
Drug
RADELUMIN 2000 MBq/ml solution injectable
Drug
Radelumin 1300 MBq/ml Injektionslösung
Drug
Radelumin 1300 MBq/ml oplossing voor injectie
Drug
RADELUMIN 2000 MBq/ml solution injectable
Drug
RADELUMIN 1300 MBq/ml solution injectable
Drug
Radelumin 1300 MBq/mL solución inyectable
Drug
Locations 5
France (1)
Germany (1)
Italy (1)
Netherlands (1)
Spain (1)
Technical details
Status
Active (not recruiting)
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male only
Minimum age
18 Years
Healthy volunteers
No
Start date
12.01.2024
Registry ID
2023-504026-19-01
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.